Sangamo Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SGMO research report →
About the company
Sangamo Therapeutics, Inc. , a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational genetically modified cell therapy TX200 in patients undergoing a kidney transplant.
- CEO
- Alexander D. Macrae Ch.B
- IPO
- 2000
- Employees
- 127
- HQ
- Richmond, CA, US
Price Chart
- Revenue
- $39.55M · -31.57%
- Net Income
- $-122,932,000 · -25.52%
- EPS
- $-0.44 · 10.20%
- Op Income
- $-108,004,000
- FCF YoY
- -44.36%
- 52W High
- $0.77
- 52W Low
- $0.06
- 50D MA
- $0.15
- 200D MA
- $0.37
- Beta
- 1.29
- Avg Volume
- 9.18M
Get TickerSpark's AI analysis on SGMO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 25, 26 | Davis Gregory D | other | 1,630 |
| May 25, 26 | Jain Nikunj | other | 1,919 |
| May 25, 26 | Dubois-Stringfellow Nathalie | other | 4,036 |
| May 25, 26 | Willoughby Scott B. | other | 4,036 |
| May 25, 26 | Macrae Sandy | other | 12,613 |
| Apr 22, 26 | Davis Gregory D | sell | 69,827 |
| Apr 21, 26 | Dubois-Stringfellow Nathalie | sell | 345,942 |
| Apr 1, 26 | Dubois-Stringfellow Nathalie | other | 800,000 |
| Apr 1, 26 | Jain Nikunj | other | 225,000 |
| Apr 1, 26 | Davis Gregory D | other | 225,000 |
Our SGMO coverage
Recent articles, reports, and earnings notes.
No research on SGMO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SGMO report →Similar companies
Peers in the same neighborhood.